CORPORATE PROFILE 
IN THIS SECTION
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a proprietary approach to harnessing the human immune system to discover and develop new products to diagnose and treat cancer. We have a robust pipeline of fully human antibody leads against multiple targets. Our lead antibody development candidate is in two phase I clinical trials. Our MVT-5873 is a therapeutic products for the treatment of pancreatic cancer and other CA 19-9 expressing tumors. The MVT-2163 product is a new generation PET imaging agent for improved imaging of pancreatic cancer. Our corporate development strategy is to partner our earlier clinical programs after proof-of-concept is established to secure non-dilutive capital for the development of additional pipeline assets. We believe this approach will create shareholder value.
IMPORTANT LINKS
 
 
SHAREHOLDER INQUIRIES

Receive Email Investor Alerts

Corporate Headquarters:
MabVax Therapeutics Holdings, Inc.
11535 Sorrento Valley Road Suite 400
San Diego, California, 92121
(T) 858-259-9405
Investor Relations:
Jenny Stephens
858-259-9405 x 302
jstephens@mabvax.com
Legal Counsel:
Sichenzia Ross Friedman Ference LLP
Transfer Agent:
Computershare Investor Services PLC